EZN-2279 in Patients With ADA-SCID

Clinical trial NCT01420627 · COMPLETED

Trial details

NCT number: NCT01420627
Sponsor: Leadiant Biosciences, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

ADA-SCID Adenosine Deaminase Deficiency Severe Combined Immunodeficiency

Start date: 2014-01-24
Primary completion: 2018-04-10
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.